Stay updated on Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial

Sign up to get notified when there's something new on the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T23:02:05.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a significant update in the treatment protocol for eligible participants with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck. The change likely reflects an adjustment in the dosage or frequency of the anti-PD-1 mAb MK-3475 (pembrolizumab) administered during reirradiation therapy.
    Difference
    0.1%
    Check dated 2024-06-06T14:49:58.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria 6' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' providing examples such as general health condition or prior treatments. Additionally, the 'Eligibility Criteria Description' now specifies that patients must have biopsy-proven locoregional recurrence or a second primary SCCHN that is unresectable or the patient is unwilling to undergo resection.
    Difference
    29%
    Check dated 2024-05-22T21:21:22.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:29:22.000Z thumbnail image

Stay in the know with updates to Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page.